BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

NCT04018248 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia
B Cell Lymphoma
Marginal Zone Lymphoma
Waldenstrom Macroglobulinemia
Peripheral T Cell Lymphoma

Interventions

DRUG: BR101801 (Phase Ia)
DRUG: BR101801 (Phase Ib)

Sponsor

Boryung Pharmaceutical Co., Ltd